This work reviews the latest findings and approaches in the use of antiangiogenic agents in cancer treatment. Material is in sections on basic biology of angiogenesis, translational research in tumor angiogenesis, and antiangiogenic therapy in clinical trial results and future directions. Chapters cover topics such as working models of tumor angiogenesis, the role of angiogenesis inhibition in the therapy of malignant disease, and the environmental influences and genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease. Other subjects examined include chemokines in angiogenesis, small-molecule vascular disrupting agents in cancer therapy, and the role of imaging in the clinical development of antiangiogenic agents. Teicher is affiliated with Genzyme Corporation. Ellis is affiliated with the University of Texas M. D. Anderson Cancer Center. Annotation ©2008 Book News, Inc., Portland, OR (booknews.com)
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer that will be useful for many years. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process. It contains chapters specific to angiogenesis and antiangiogenic treatment of many malignant diseases. Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.
